Published in Medical Letter on the CDC and FDA, December 19th, 2004
However, older patients with diabetes mellitus taking combined statin-fibrate therapy appear to be at an increased risk for rhabdomyolysis. And patients who were taking cerivastatin combined with fibrates had a significantly higher risk of about 1 in 10 treated patients each year. Cerivastatin was removed from the U.S. market in 2001 because of high reporting of rhabdomyolysis in association with its use. The study,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA